These lines of evidence strongly suggest that SCFFbxw2 is an essential mediator of KSRP‐dependent proinflammatory responses in obesity‐associated metabolic disorders and that suppression of KSRP degradation is a feasible strategy to treat metabolic diseases. Here, KHSRP is linked to metabolic disease.